Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

ClinicalTrials.gov ID: NCT02512926

Public ClinicalTrials.gov record NCT02512926. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.

Study identification

NCT ID: NCT02512926
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Stanford University; Other
Enrollment: 4 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 6 Months to 29 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 15, 2016
Primary completion: Aug 27, 2021
Completion: Nov 6, 2023
Last update posted: Oct 14, 2025

2016 – 2023

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Phoenix Children's Hospital	Phoenix	Arizona	85016	—
Arkansas Children's Hospital	Little Rock	Arkansas	72202	—
Stanford University School of Medicine and Stanford Cancer Institute	Palo Alto	California	94304	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	—
Penn State Hershey Children's Hospital	Hershey	Pennsylvania	17033-0850	—
University of Texas Health Science Center at San Antonio	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02512926, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 14, 2025 · Synced Sep 28, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02512926 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →